Mounjaro Becomes India’s Top-Selling Drug, Hits ₹100 Crore in October Sales

Eli Lilly’s Mounjaro, a medicine for obesity and diabetes, has become India’s top-selling drug in October. It earned ₹100 crore ($11.38 million) in just one month. The drug was launched in India in March 2025 and quickly became popular. Mounjaro’s rise shows how people in India are looking for effective treatments for diabetes and obesity. Around 101 million people in India, or 11.4 percent of the population, live with diabetes, according to a 2023 study published in The Lancet.

Mounjaro is an injectable medicine used for people with type 2 diabetes who are overweight or obese. It works by targeting two important hormones in the body, GLP-1 and GIP. These hormones help control blood sugar and appetite, making it easier for people to manage weight and improve health. Doctors say that by slowing digestion and controlling hunger, Mounjaro can support steady weight loss in a safe way.

Since its launch, Mounjaro has sold far more than its competitor Wegovy, launched by Novo Nordisk in June. In October, the volume of Mounjaro used in India was ten times higher than Wegovy. The drug has generated ₹333 crore in revenue since March. Many studies also suggest that tirzepatide, the medicine in Mounjaro, can help people lose more weight than semaglutide, sold as Ozempic.

Experts say that while Mounjaro is effective, it is not a quick solution for everyone. It should be taken under medical guidance, especially for people with diabetes or other health conditions. The success of the drug highlights the growing need for treatments that can manage both blood sugar and weight in India. With rising rates of diabetes and obesity, medicines like Mounjaro are becoming an important part of healthcare planning.

The drug’s popularity also shows that more people are aware of their health and are willing to explore treatments that can improve their quality of life. However, doctors caution that lifestyle changes like healthy diet, regular exercise, and balanced nutrition remain essential alongside any medicine.

Mounjaro’s rapid success reflects a new trend in India where modern medicines for obesity and diabetes are in high demand. It shows that people are looking for safe and effective ways to manage health problems that affect millions across the country.